Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof

US9359372B2 · kind B2 · utility

Assignee

• SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES · CN

Inventors

• Hong Liu · Shanghai, CN
• Xin XIE · Shanghai, CN
• Xuechu ZHEN · Shanghai, CN
• Haifeng Sun · Suzhou, CN
• Jing Li · Lansdale, US
• Liyuan ZHU · Shanghai, CN
• Zeng Li · Pudong New District, CN
• Ying Chen · Los Angeles, US
• Hualiang Jiang · Shanghai, CN
• Kaixian Chen · Shanghai, CN

Key dates

• Filing date: Apr 10, 2015
• Grant date: Jun 7, 2016
• Expiry date: Apr 10, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/22
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.